Search clinical trials for: SAR442257

Total 2 results

Sanofi

Active, not recruiting

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Neoplasm Malignant

Korea, Republic of, Spain, Czechia, United States, Norway
Sanofi

Completed

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Overweight | Healthy Subjects

United States

3

Subscribe